Durvalumab (MEDI4736; anti-PD-L1 inhibitor): to shed light on the treatment of advanced urothelial bladder cancer patients refractory to systemic chemotherapy

2016 ◽  
Vol 5 (S3) ◽  
pp. S454-S457
Author(s):  
Minyong Kang ◽  
Ja Hyeon Ku
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Systemic Chemotherapy ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Shed Light

905 Hypoxia is independently associated with poor outcome in urothelial bladder cancer patients treated with radical cystectomy

2012 ◽  
Vol 11 (1) ◽  
pp. e905-e905a
Author(s):  
P.J. Bostrom ◽  
J. Thoms ◽  
B.W.G. Van Rhijn ◽  
O. Ahmed ◽  
O. Stakhovskyi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Radical Cystectomy ◽  
Urothelial Bladder Cancer ◽  
Poor Outcome ◽  
Urothelial Bladder

Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients

Cancer ◽  
2009 ◽  
Vol 115 (3) ◽  
pp. 517-523 ◽  
Author(s):  
Giuseppe Di Lorenzo ◽  
Vincenzo Montesarchio ◽  
Riccardo Autorino ◽  
Teresa Bellelli ◽  
Nicola Longo ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Phase 1 ◽  
Oral Cyclophosphamide ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder
Sign in / Sign up

Export Citation Format

Share Document